Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tenofovir alafenamide (Vemlidy®) cannot be endorsed for use within NHS Wales for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg). |
||
|
||
Medicine details |
||
| Medicine name | tenofovir alafenamide (Vemlidy®) | |
| Formulation | film-coated tablet | |
| Reference number | 2567 | |
| Indication | For the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg). |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 24/07/2017 | |
| Date of issue | 25/07/2017 | |